Reuters Pharma Europe 2025 | pharmaphorum

Skip to main content

Friday 20 March 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Reuters Pharma Europe 2025

Market Access

Reuters Europe 2025: Using value propositions to improve access

Reuters Europe 2025: Using value propositions to improve acc...

In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.

Market Access

Reuters Europe 2025: Trade-offs in European launch sequencing

Reuters Europe 2025: Trade-offs in European launch sequencin...

At Reuters, industry stakeholders discussed how, especially in light of the current tariff crisis, Europe must operate as a unit when pricing drugs.

Market Access

Reuters Europe 2025: Collaboration key for innovation, BI head says

Reuters Europe 2025: Collaboration key for innovation, BI he...

At Reuters Pharma Europe, Francesco Di Marco of Boehringer Ingelheim focused on the importance of innovating together.

Digital

Reuters Pharma Europe 2025: Access, AI dominate keynote talks

Reuters Pharma Europe 2025: Access, AI dominate keynote talk...

The opening sessions of Reuters Pharma Europe 2025 focused on global access challenges and the transformative potential of AI.

Editor's Picks

NVIDIA sinks $2bn into AI cloud provider Nebius

Incyte breaks new ground in anal cancer with EU approval

Novo rapped by FDA for not reporting drug adverse effects

Iran hackers claim cyberattack at US medtech firm

Veeva buys brand engagement firm Ostro for $100m

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company